First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.
Saved in:
| Title: | First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer. |
|---|---|
| Authors: | Heymach JV; Department of Thoracic/Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston., Yamamoto N; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo., Girard N; Institut Curie, Institut du Thorax Curie-Montsouris, Paris.; Paris-Saclay University, Université de Versailles Saint-Quentin-en-Yvelines, Versailles, France., Ruiter G; Department of Clinical Pharmacology, Netherlands Cancer Institute, Amsterdam.; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam., Smit EF; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam.; Department of Pulmonary Diseases, Leiden University Medical Center, Leiden, the Netherlands., Planchard D; Department of Medical Oncology, Institut Gustave Roussy, Thoracic Group and International Center for Thoracic Cancers, Villejuif, France.; Faculty of Medicine, Paris-Saclay University, Paris., Nadal E; Thoracic Tumors Unit, Medical Oncology, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute, L'Hospitalet de Llobregat, Barcelona., Wu YL; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China., Zugazagoitia J; Department of Medical Oncology, 12 de Octubre Hospital, Madrid., Tu HY; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China., Baik CS; Thoracic, Head and Neck Medical Oncology, Fred Hutchinson Cancer Center, University of Washington, Seattle., Yoh K; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Soo RA; Department of Hematology-Oncology, National University Cancer Institute, Singapore., Zhao Y; Department of Medical Oncology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China., Sabari JK; Division of Medical Oncology, Perlmutter Cancer Center, New York University Langone Health, New York., Wermke M; National Center for Tumor Diseases-University Cancer Center Early Clinical Trial Unit, Technische Universität Dresden, Dresden, Germany., Scheffler M; Department I of Internal Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany., Ahn MJ; Department of Hematology and Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Fernamberg K; Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT., Schroeter L; Boehringer Ingelheim Pharma, Biberach an der Riss, Germany., Sadrolhefazi B; Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT., Thamer C; Boehringer Ingelheim Pharma, Biberach an der Riss, Germany., Eigenbrod-Giese S; Boehringer Ingelheim International, Ingelheim am Rhein, Germany., Popat S; Lung Unit, Royal Marsden Hospital, London.; Division of Clinical Studies, Institute of Cancer Research, London. |
| Corporate Authors: | Beamion LUNG-1 Investigators |
| Source: | The New England journal of medicine [N Engl J Med] 2026 Apr 30; Vol. 394 (17), pp. 1675-1684. Date of Electronic Publication: 2026 Apr 15. |
| Publication Type: | Journal Article; Clinical Trial, Phase I; Multicenter Study |
| Journal Info: | Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1533-4406 (Electronic) Linking ISSN: 00284793 NLM ISO Abbreviation: N Engl J Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
